Conceivable Life Sciences has secured $50 million in Series A funding led by Advance Venture Partners to accelerate development of its AI-powered automated IVF laboratory platform. Existing investors ARTIS Ventures, Stride, and ACME participated in the round, bringing total funding to $70 million.
The New York-based company has developed AURA, which it describes as the world’s first automated IVF lab platform. The system uses robotic precision and AI algorithms to standardize the more than 200 steps involved in IVF procedures, aiming to reduce variability in outcomes.
Traditional IVF labs rely on manual processes that can introduce inconsistency in results. Conceivable’s platform automates the delicate procedures involved in combining sperm and egg to create embryos, applying robotics and AI to what has historically been performed manually.
“This funding validates our vision of transforming IVF through AI-powered robotic automation,” said Alan Murray, co-founder and CEO of Conceivable. “Our platform addresses the core challenges facing fertility clinics today—unpredictable success rates, capacity constraints, and accessibility barriers. This investment allows us to accelerate our bringing this groundbreaking technology to market.”
The company is conducting a 100-patient pilot study and reports positive early pregnancy results. “Ongoing pregnancy results from the current trial are quite positive and we have 18 healthy babies from an earlier study on prototype instruments,” said Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Medical Officer of Conceivable. “Early indications from clinical KPIs are very promising and demonstrate that robotic precision and AI-driven protocols will outperform traditional manual approaches. We are committed to delivering consistent outcomes that fertility patients deserve.”
The funding will support Conceivable’s U.S. market launch in 2026, with plans to expand partnerships with fertility networks. The company aims to address rising demand for IVF services, which experts estimate could be 10 times current capacity.
“The fertility industry stands at a critical inflection point where breakthrough innovation will fundamentally expand access to care,” said Alex Christ, General Partner at Advance Venture Partners. “We saw a fragmented landscape of companies building low impact, point solutions for individual IVF processes, but only Conceivable tackling the full end-to-end approach to IVF that truly pushes the industry forward. By integrating these complex steps in one system, they’ve revolutionized the IVF lab with technology, engineering, and biology at the core. Conceivable’s technology will enable the entire sector to deliver fertility care that’s more consistent, scalable, and – most importantly – within reach for the families who need it most.”
